A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

477

Participants

Timeline

Start Date

April 22, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions
Blepharitis
Interventions
DRUG

Pimecrolimus 0.3% Ophthalmic Ointment

Pimecrolimus 0.3% Ophthalmic Ointment will be applied twice a day to both eyelid margins.

DRUG

Placebo Ophthalmic Ointment

Placebo will be applied twice a day to both eyelid margins.

Trial Locations (29)

16066

Clinical Investigator Site, Cranberry Township

21078

Clinical Investigator Site, Havre de Grace

24502

Clinical Investigator Site, Lynchburg

27529

Clinical Investigator Site, Garner

30260

Clinical Investigator Site, Morrow

30339

Clinical Investigator Site, Atlanta

33603

Clinical Investigator Site, Tampa

33773

Clinical Investigator Site, Largo

34429

Clinical Investigator Site, Crystal River

37167

Clinical Investigator Site, Smyrna

40206

Clinical Investigator Site, Louisville

45242

Clinical Investigator Site, Cincinnati

55340

Clinical Investigator Site, Medina

63090

Clinical Investigator Site, Washington

63131

Investigative Site, St Louis

64154

Clinical Investigator Site, Kansas City

66762

Clinical Investigator Site, Pittsburg

78229

Clinical Investigator Site, San Antonio

78731

Clinical Investigator Site, Austin

78738

Clinical Investigator Site, Lakeway

80045

Clinical Investigator Site, Aurora

84015

Clinical Investigator Site, Clinton

85032

Clinical Investigative Site, Phoenix

90301

Clinical Investigator Site, Inglewood

91204

Clinical Investigator Site, Glendale

92663

Clinical Investigator Site, Newport Beach

92843

Clinical Investigator Site, Garden Grove

94954

Clinical Investigator Site, Petaluma

95670

Clinical Investigator Site, Rancho Cordova

All Listed Sponsors
lead

Famy Life Sciences, a Viatris Company

INDUSTRY

NCT06400511 - A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment | Biotech Hunter | Biotech Hunter